I have posted about $vyne before but I want to make a thread to more fully explain the hypothesis and why it has such asymmetric r/r. Vyne has two assets, VYN2O1 and VYN202 that have very different levels of risk and upside potential, creating a highly asymmetric package.

@jeromeleonard5 @Phoenix3million Why is it only a week to wait.

@Phoenix3million @jeromeleonard5 Prob the Amgen collab termination. They have their own prmt5 now but will need to do mono dose escalation before they can combo.

@LabbRadar My read (not sure if true) is that market thinks company was seeing blinded blended data and ceo is leaving because that data is disappointing.

@Aesculapius1898 @AppleHelix Weirdness of difference in response at 12 vs 14 weeks

@AppleHelix For sure. What is your bar for 28 week data.

Shorts are doubling down in $crdf. Either this will turn into $alxo / $syrs or the squeeze will be epic. Def not impossible for randomized data to collapse as n grows, but the n=15 bev naive 2l + good randomized data make me think shorts are wrong here.

@BayAreaBiotechI I would like to see the week 12 naive vs exp, but week 14 being a total anomaly seems less likely to me than that drug takes a while to work. R/R for shorts at current prices seems terrible into 28 week data imo.

@BiotechObserver @LY4101174 Yes, they did not drop any patients off the week 14 data. Stock should be up on this but people talking their book are criticizing it on twitter + shitty cpi print so it is dumping for now.

@2_Simple_Naive Delta at week 14 is massive. I agree seeing the week 12 days for naive vs exp would be nice but I think they pretty clearly have a real drug. .

@BioValues Shorts are gunna be feeling serious pain in $anab as well but might lead to some degrossing so not sure of net effect.

@Biohazard3737 Still don’t think $lly buys them but nice contrarian call on this one.

@2_Simple_Naive What don’t you like in the data.

@Sharky51822379 Patients that failed screening maybe.

@BowTiedBiotech Upside likely much higher. Almost all approved ra drugs become blockbusters. Question is if it is commercially viable and they will go to phase 3.

@JialiangLiang @AlpBugraBasat Post pd1? Seems like 0 chance for 1l.

@MarcJacksonLA Wrong tag. $lctx

@Phoenix3million Last few days there has been a strong buyer that didn’t show up til last 15-20 minutes. I think it will be back in 3s soon

@badinvestor99 @houndcl I dont think that is true, especially in AD (really don’t get why arqt didn’t test higher concentration there as well)